Overview

* SELLAS Q3 net loss narrows to $6.8 mln from $7.1 mln a year ago

* Company's cash position strengthened by $29.1 mln from warrant exercises in October

* Phase 3 REGAL trial of GPS and Phase 2 SLS009 program progressing as planned

Outlook

* SELLAS expects final analysis of Phase 3 REGAL trial by year-end 2025

* Company plans to start SLS009 trial in newly diagnosed AML patients in Q1 2026

Result Drivers

* R&D EXPENSES - Declined by $0.2 mln

primarily due to lower clinical trial expenses and clinical and regulatory consulting costs

* G&A EXPENSES - Fell by $0.1 mln

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Net -$6.79

Income mln

Q3 Basic -$0.06

EPS

Q3 $7.08

Operatin mln

g

Expenses

Q3 -$7.08

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Sellas Life Sciences Group Inc ( SLS ) is $7.00, about 78.4% above its November 11 closing price of $1.51

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)